Access Keys:
Skip to content (Access Key - 0)

Center For Cancer Research National Cancer Institute
JB6 Mouse Model

JB6 Mouse Model

The mouse Balb/C JB6 model (1) is the only well characterized model of genetic variants for a neoplastic transformation response to tumor promoters. These cells are not differentially sensitive to tumor promoter induced mitogenesis or differentiation (2), thus increasing the likelihood that molecular response differences will be transformation-relevant. These cells are also not differential at the level of tumor promoter receptors such as protein kinase C or epidermal growth factor receptor, thus indicating that these are post-receptor signaling variants (3). Moreover the JB6 response variants are stably free of spontaneous transformation (a property found to be mouse strain dependent) and stably responsive (P+) or nonresponsive (P-) to tumor promoter induced transformation. Thus molecular events that occur only in the P+ cells are candidates for mediating tumor promotion while those that occur only in the P- cells are candidate inhibitors. The JB6 model is not suitable for studying epidermal differentiation or keratin synthesis. The JB6 model is uniquely suited for studying tumor promotion and promotion-relevant molecular events. Research using the Balb/C mouse JB6 model of transformation response variants has yielded milestones that propelled research in several areas.

Mechanistic Insights

The JB6 model was among the first (along with those reported by M. Oren and his colleagues (4) in which expression of a mutant of the tumor suppressor p53 was shown to produce a gain of oncogenic response (5). The first cloning of mouse TIMP-3 was done as part of a differential display analysis of JB6 cells (6). The demonstration that TIMP-3 functions as a tumor suppressor in human colon carcinoma cells (7) was supported by others who isolated TIMP-3 by gene trapping (8). The first observation of a requirement for active oxygen generation in tumor promotion was made with JB6 cells (9) and has been followed up extensively (10-15). The ubiquitous secreted cell adhesion glycophosphoprotein osteopontin was first cloned in 1987 from JB6 cells by subtractive hybridization (16). Osteopontin expression plays important roles in tumor promotion and tumor progression, inflammation, bone remodeling and other processes (17-19). The 1989 discovery (20) and subsequent reports (21, 22) that the JB6 transformation variants are also AP-1 response variants stimulated the demonstration that AP-1 activation is causal for progression/invasion (23, 24), maintenance (25), and induction (26) of tumor phenotype in mouse cell culture models. These findings stimulated in vivo investigations that implicated cFos in papilloma-to- carcinoma progression but not in tumor promotion (papilloma induction) (27). That tumor promotion in vivo requires AP-1 activation was first established using dominant negative jun(TAM67) expressing transgenic mice (28). Transformation relevant pathways to AP-1 activation have been elucidated in JB6 cells, implicating MAP kinase ERK activation (29, 30). The ERK requirement for AP-1 activation has been extended to AP-1 activation by UVB (31) and by arsenite (32). The observation that UVB activates AP-1 has been extended from JB6 cells to human keratinocytes (33, 34) and to mouse skin in vivo (35, 36). NF B-dependent gene expression is also required for transformation in the JB6 model (14). P- cells are nonresponsive for NF B activation (14). Inducible nitric oxide synthase (iNOS) is induced in P+ but not in P- JB6 cells cocultured with an interferon-stimulated macrophage cell line (37). INOS induction is NF B-dependent. iNOS is one of a small set of genes that appears to be targeted in mice expressing AP-1/NF B inhibitor (TAM67) (Young et al., unpublished).

Cancer Prevention

In addition to propelling mechanistic insights, studies with the JB6 model have impacted research in cancer prevention. A number of tumor promotion inhibitors studied in the JB6 model have been discovered to owe their transformation inhibiting activity at least in part to their AP-1 repressing activity. Among these inhibitors are turmeric-derived curcumin (38), aspirin (39), the tea polyphenol EGCG (40-42), potato proteinase inhibitors (43, 44), gingerol (45), citrifolin A (46), Omega 3 fatty acids (47), and novel glycosides (48). Some of these inhibitors have been shown to target AP-1 also in mouse skin (35). Recently Birt and colleagues have discovered that the basis for caloric restriction inhibiting tumor promotion lies at least in part, in its inhibition of ERK and AP-1 activation (49, 50). Other molecular targets of cancer prevention agents have been identified using the JB6 model. The grape skin inhibitor resveratrol activates p53 (51).

Cancer Risk Assessment

Finally, the JB6 model has also been valuable for cancer risk assessment. The sensitivity of the JB6 model has made it possible to convincingly conclude that exposure to electric and magnetic fields around power lines poses little or no human risk (52, 53). Environmental metals such as arsenic and vanadium have been shown to act as tumor promoters in the JB6 model (32, 54).

In summary the use of the mouse JB6 model has spawned a number of advances not only in basic cell biology but also in understanding the molecular mechanism of tumor promotion. Moreover these studies have contributed to progress in cancer prevention and risk assessment research. Many of these advances have been extended from the JB6 model to human epithelial cell (solid tumor) progression models or to in vivo mouse multistage carcinogenesis models. This progress reflects a response of many laboratories to the unique opportunities for discovery presented by the mouse JB6 model.


1. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. Nature 281: 589-591, 1979.
2. Colburn NH, Wendel EJ, Abruzzo G. issociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci USA 78: 6912-6916, 1981.
3. Colburn NH, Gindhart TD, Hegamyer GA, Blumberg PM, Delclos KB, Magun BE, Lockyer J. Phorbol diester and epidermal growth factor receptors in 12-O- tetradecanoylphorbol-13-acetate-resistant and -sensitive mouse epidermal cells. Cancer Res 42: 3093-3097, 1982.
4. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence- specific DNA binding. Mol Cell Biol 12: 5581-5592, 1992.
5. Sun Y, Nakamura K, Wendel E, Colburn N. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci US A 90: 2827-2831, 1993.
6. Sun Y, Hegamyer G, Colburn NH: Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res 54: 1139-1144, 1994.
7. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, Kung HF, Colburn NH, Sun Y. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17: 1805-1811, 1996.
8. Andreu T, Beckers T, Thoenes E, Hilgard P, von Melchner H. Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem 273: 13848-13854, 1998.
9. Nakamura Y, Colburn NH, Gindhart TD. Role of reactive oxygen in tumor promotion: implication of superoxide anion in promotion of neoplastic transformation in JB-6 cells by TPA. Carcinogenesis 6: 229-235, 1985.
10. Crawford D, Zbinden I., Amstad P, Cerutti P. Oxidant stress induces the protooncogenes c-fos and c-myc in mouse epidermal cells. Oncogene 3: 27-32, 1988.
11. Ghosh R, Amstad P, Cerutti P. UVB-induced DNA breaks interfere with transcriptional induction of c- fos. Mol Cell Biol 13: 6992-6999, 1993.
12. Amstad PA, Liu H, Ichimiya M, Chang S, Berezesky IK, Trump BF. bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells. Mol Carcinog 20: 231-239, 1997.
13. Gupta A, Rosenberger SF, Bowden GT. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 20: 2063-2073, 1999.
14. Hsu TC, Nair R, Tulsian P, Hegamyer G, Young MR, Colburn NH. Transformation non-responsive cells owe their resistance to lack of NF- B activation. Cancer Res 61: 4160-4168, 2001.
15. Hsu TC, Young MR, Cmarik J, Colburn NH.Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28: 1338-48, 2000.
16. Craig AM, Smith JH, Denhardt DT. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem 264: 9682-9689, 1989.
17. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749, 2001.
18. Chang PL, Prince CW. 1 alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res 51: 2144-2150, 1991.
19. Chang PL, Chambers AF: Transforming JB6 cells exhibit enhanced integrin- mediated adhesion to osteopontin. J Cell Biochem 78: 8-23, 2000.
20. Bernstein LR, Colburn NH.AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244: 566-569, 1989.
21. Ben-Ari ET, Bernstein LR, Colburn NH. Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation. Mol Carcinog 5: 62-74, 1992.
22. Bernstein LR, Bravo R, Colburn N. H. 12-O-tetradecanoylphorbol-13-acetate- induced levels of AP-1 proteins: a 46-kDa protein immunoprecipitated by anti-fra-1 and induced in promotion-resistant but not promotion-sensitive JB6 cells. Mol Carcinog 6: 221-229, 1992.
23. Hennigan RF, Hawker KL, Ozanne BW. Fos-transformation activates genes associated with invasion. Oncogene 9: 3591-3600, 1994.
24. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD, Ozanne BW. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17: 963-976, 1997.
25. Domann FE, Levy JP, Birrer MJ, Bowden GT. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ 5: 9-16, 1994.
26. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 91: 609-613, 1994.
27. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM. c-fos is required for malignant progression of skin tumors. Cell 82: 721-732, 1995.
28. Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 96: 9827-9832, 1999.
29. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17: 3493-3498, 1998.
30. Huang C, Ma WY, Young MR, Colburn N, Dong Z. Shortage of mitogen- activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A 95: 156-161, 1998.
31. Huang C, Ma WY, Dong Z. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells. Oncogene 18: 2828- 2835, 1999.
32. Huang C, Ma WY, Li J, Goranson A, Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 274: 14595-14601, 1999.
33. Chen W, Borchers AH, Dong Z, Powell MB, Bowden GT. UVB irradiation- induced activator protein-1 activation correlates with increased c-fos gene expression in a human keratinocyte cell line. J Biol Chem 273: 32176-32181, 1998.
34. Barthelman M, Bair WB 3rd, Stickland KK, Chen W, Timmermann BN, Valcic S, Dong Z, Bowden GT. Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 19: 2201-2204, 1998.
35. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 272: 26325-26331, 1997.
36. Barthelman M, Chen W, Gensler H. L, Huang C, Dong Z, Bowden GT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 58: 711-716, 1998.
37. Murakami A, Kawabata K, Koshiba T, Gao G, Nakamura Y, Koshimizu K, Ohigashi H. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon- gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. Cancer Res 60: 6326-6331, 2000.
38. Lu YP, Chang RL, Lou YR, Huang MT, Newmark HL, Reuhl KR, Conney AH. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis. Carcinogenesis 15: 2363-2370, 1994.
39. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 272: 9962-9970, 1997.
40. Dong Z, Ma W, Huang C, Yang CS. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, epigallocatechin gallate, and theaflavins. Cancer Res 57: 4414-4419, 1997.
41. Nomura M, Ma WY, Huang C, Yang CS, Bowden GT, Miyamoto K, Dong Z. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea. Mol Carcinog 28: 148-155, 2000.
42. Nomura M, Ma W, Chen N, Bode AM, Dong Z. Inhibition of 12-O- tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, epigallocatechin gallate and theaflavins. Carcinogenesis 21: 1885-1890, 2000.
43. Huang C, Ma WY, Ryan CA, Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV- induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc Natl Acad Sci U S A 94: 11957-11962, 1997.
44. Liu G, Chen N, Kaji A, Bode AM, Ryan CA, Dong Z. Proteinase inhibitors I and II from potatoes block UVB-induced AP-1 activity by regulating the AP-1 protein compositional patterns in JB6 cells. Proc Natl Acad Sci USA 98: 5786-5791, 2001.
45. Bode AM, Ma WY, Surh YJ, Dong Z. Inhibition of epidermal growth factor- induced cell transformation and activator protein 1 activation by. Cancer Res 61: 850- 853, 2001.
46. Sang S, He K, Liu G, Zhu N, Cheng X, Wang M, Zheng Q, Dong Z, Ghai G, Rosen RT, Ho CT. A new unusual iridoid with inhibition of activator protein-1 (AP-1) from the leaves of Morinda citrifolia L. Org Lett 3: 1307-1309, 2001.
47. Liu G, Bibus DM, Bode AM, Ma WY, Holman RT, Dong Z. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proc Natl Acad Sci USA 98: 7510-7515, 2001.
48. Liu G, Bode A, Ma WY, Sang S, Ho CT, Dong Z. Two novel glycosides from the fruits of morinda citrifolia (noni) inhibit ap-1 transactivation and cell transformation in the mouse epidermal jb6 cell line. Cancer Res 61: 5749-5756, 2001.
49. Liu Y, Duysen E, Yaktine AL, Au A, Wang W, Birt DF. Dietary energy restriction inhibits ERK but not JNK or p38 activity in the epidermis of SENCAR mice. Carcinogenesis 22: 607-612, 2001.
50. Birt DF, Yaktine A, Duysen E. Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. J Nutr 129: 571S-574S, 1999.
51. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61: 1604-10., 2001.
52. Saffer JD, Chen G, Colburn NH, Thurston SJ. Power frequency magnetic fields do not contribute to transformation of JB6 cells. Carcinogenesis 18: 1365-1370, 1997.
53. West RW, Hinson WG, Swicord ML. Anchorage-independent growth with JB6 cells exposed to 60 HZ magnetic fields at several flux densities. Bioelectrochemistry & Bioenergetics 39: 175-179, 1996.
54. Ding M, Li J-J, Leonard SS, Ye J-P, Shi X, Colburn NH, Castranova V and Vallyathan V. Vanadate-induced activation of activator protein-1: Role of reactiveoxygen species. Carcinogenesis 20: 663-668, 1999.